The venerable learned-intermediary doctrine protects drugmakers from a great deal of ill-founded litigation alleging failure to warn, by making clear that they've discharged their duty if they adequately warn the doctor who prescribes the compound. But as Beck & Herrmann warn, some folks in Albany would like to change that. A05201/S 3157 is sponsored by Assemblymen Richard Brodsky (D-Westchester) and Harvey Weisenberg (D-Nassau).
New York Assembly bill could open pharmaceutical litigation floodgates
Related Entries:
- Greg Conko: Can brand makers be sued for generic drug injuries?
- Greg Conko discusses the FDA's ban on off-label promotion
- Hearing: Can We Sue Our Way Into Prosperity?
- Around the web, January 27
- National debt commission recommends medical liability reform
- Told-you-so dept.: USDOT exonerates Toyota
- "Disclosed to Death"
- Health care tort reform: Improving the culture of communication?
- "Use of a headset that covers both ears will impair your ability to hear other sounds"
- A $500 million damage award hardly makes news anymore
- $10 million verdict against ambulance service
- Retention battle ahead for Illinois justice?
- The medical liability language in the health care law
- Nothing new, no money for tort reform in latest health care bills
- "Thimerosal-autism test cases dismissed"
![]() |
| Isaac Gorodetski Project Manager, Center for Legal Policy at the Manhattan Institute igorodetski@manhattan-institute.org |
![]() |
| Laura Eyi Press Officer, Manhattan Institute leyi@manhattan-institute.org |



